Previous close | 6.81 |
Open | 6.70 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 22.50 |
Expiry date | 2026-01-16 |
Day's range | 6.70 - 6.81 |
Contract range | N/A |
Volume | |
Open interest | 8.13k |
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.